Behavioural Brain Research
July 14, 2022
Marina Goulart Da Silva, Guilherme Cabreira Daros, Fabiana Pereira Santos et al.
22 citations
Ayahuasca reduced anxiety-like and depressive-like behaviors in rats with neuroinflammation induced by lipopolysaccharide (0.63 mg/kg/mL). Eighty male rats, about 90 days old, were divided into control and LPS groups, with prevention and treatment subgroups. Ayahuasca (4 mL/kg) or saline was given by gavage one hour before or 24 hours after LPS or saline injections. Open field and forced swimming tests measured behavior. LPS rats given ayahuasca showed less anxiety-like behavior in both subgroups. Depressive-like behavior decreased in LPS rats given ayahuasca, in both prevention and treatment subgroups, compared to controls. The findings suggest anxiolytic and antidepressant potential of ayahuasca in neuroinflammation, possibly via antineuroinflammatory effects.
Molecular neurobiology
May 1, 2025
Rick Wilhiam de Camargo, Larissa Joaquim, Richard Simon Machado et al.
13 citations
Pretreatment with the psychoactive decoction Ayahuasca (AYA) for three days before inducing sepsis in rats reduced anxiety-like behaviors and neuroinflammation. AYA increased time spent in the open arms of an elevated plus maze and prevented excessive grooming and rearing, indicating anxiolytic effects. It raised levels of the anti-inflammatory cytokine interleukin-4 in the prefrontal cortex and cortex and brain-derived neurotrophic factor in the cortex. AYA also increased myeloperoxidase activity in the prefrontal cortex and hippocampus while decreasing nitrite/nitrate concentrations across multiple brain regions, suggesting enhanced neutrophil activation and reduced nitric oxide signaling. Additionally, AYA prevented lipid peroxidation in the prefrontal cortex, hippocampus, and cortex. These findings suggest AYA may protect against sepsis-induced neuroinflammation, oxidative stress, and anxiety-like symptoms.
European archives of psychiatry and clinical neuroscience
March 1, 2025
Arilton Martins Fonseca, Rafael Guimarães Dos Santos, Lívia Soman de Medeiros et al.
10 citations
Long-term ritualistic ayahuasca use, spanning over 20 years, does not impair cognition and may be linked to better working memory compared to short-term use. In a study of 48 participants from a Santo Daime church in Brazil, experienced users (over 20 years) scored higher on tests of verbal and visuospatial working memory than beginners (under 3 years). No evidence of cognitive decline was found among ayahuasca users. The control group, matched by sex, age, and education, showed similar cognitive performance. The brew's botanical identities and alkaloid content were confirmed.
Journal of clinical psychopharmacology
Lucas Silva Rodrigues, José Augusto Silva Reis, Giordano Novak Rossi et al.
8 citations
A single dose of ayahuasca, a plant hallucinogen containing N,N-dimethyltryptamine and harmine, was given with psychological support to 11 college students who drank alcohol harmfully. The treatment was well tolerated and produced strong psychoactive effects. Days of alcohol consumption per week dropped from about 2.9 to 2.1 between weeks 2 and 3, but this reduction was not statistically significant after correcting for multiple comparisons. No other measures—craving, anxiety, impulsivity, self-esteem, or social cognition—showed significant changes, except faster reaction time on an empathy task. The small sample and mild baseline drinking likely limited the findings. The study demonstrates the protocol is feasible for future larger trials.
Behavioural brain research
May 8, 2025
Larissa da Silva Joaquim, Lara Rodrigues da Rosa, Yasmin Strickert et al.
5 citations
Ayahuasca, a decoction containing β-carbolines and DMT, reversed stroke-induced increases in the inflammatory markers IL-6, IL-10, and MPO activity in the prefrontal cortex and hippocampus of rats, and reduced oxidative stress markers TBARS in the prefrontal cortex and hippocampus. It also modulated mitochondrial enzyme activity in the hippocampus and cortex. However, ayahuasca did not improve neurological deficits, locomotion, anxiety-like behavior, or recognition memory. These molecular changes suggest a neuroprotective role against ischemia-induced neuroinflammation and oxidative stress, though without corresponding functional improvements in this three-day treatment study.
Psychoactives
November 17, 2023
Anna Beatriz Vicentini, Lucas Silva Rodrigues, Giordano Novak Rossi et al.
4 citations
In a single-blind study, university students aged 18 to 24 with harmful alcohol use received one dose of ayahuasca (1 mL/kg). Twenty-one days later, semi-structured interviews with six participants identified psychological elements linked to reduced drinking. Content analysis revealed categories including Positive Impacts, Substance Use Pattern, and Insights. Together, these categories suggest that insights and positive emotions from the experience may foster internal transformation, potentially leading to decreased alcohol consumption.
Talanta
January 27, 2026
Fabiana Pereira Santos, Beatriz Aparecida Passos Bismara Paranhos, Thaisa Meira Sandini et al.
A greener analytical method using dispersive liquid-liquid microextraction and LC-MS/MS was developed to measure N,N-dimethyltryptamine (DMT) and three β-carbolines (harmine, harmaline, tetrahydroharmine) in human hair. The method was sensitive, with limits of quantification from 3 to 8 pg/mg, and linear up to 1000 pg/mg. Recovery was low (36-58%), but selectivity showed no interference. Applied to six real samples, DMT concentrations ranged from 21.5 to 204.4 pg/mg, while β-carbolines were generally higher, with harmine reaching over 1000 pg/mg. The method uses less organic solvent than conventional hair extraction, advancing green analytical toxicology for psychoactive alkaloids.
Psychopharmacology
October 31, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca, a brew containing DMT and β-carbolines used in indigenous rituals, has shown potential for treating substance use disorders. In C57Bl/6 mice, ayahuasca at a high dose (15 mg DMT/kg) induced rewarding effects, but these were weaker than those of cocaine. When mice were conditioned with cocaine and later treated with ayahuasca (12.5 or 15 mg DMT/kg), the brew prevented the reinstatement of cocaine-induced conditioned place preference after a cocaine challenge. The findings suggest ayahuasca may have therapeutic value for cocaine use disorder by reducing relapse to drug-seeking behavior.
Research Square
July 25, 2025
Vítor Bruno, Lídia Emmanuela Wiazowski Spelta, Matheus Lujan Pereira et al.
Ayahuasca, a psychedelic brew used in indigenous rituals, reduced the reinstatement of cocaine-induced conditioned place preference in C57Bl/6 mice, suggesting potential for treating cocaine use disorder. While ayahuasca itself produced rewarding effects at the highest dose tested (15 mg DMT/kg), these were weaker than those of cocaine (10 mg/kg). Treatment with ayahuasca (12.5 or 15 mg DMT/kg) after cocaine conditioning and before a cocaine challenge effectively prevented the reactivation of drug-associated contextual preference. The findings indicate therapeutic value for ayahuasca in cocaine use disorder, though research in humans remains limited.